A Review of Type 1 and Type 2 Intraductal Papillary Neoplasms of the Bile Duct

Abstract

Intraductal papillary neoplasm of the bile duct (IPNB) is a heterogeneous disease similar to intraductal papillary mucinous neoplasm of the pancreas. These lesions have been recognized as one of the three major precancerous lesions in the biliary tract since 2010. In 2018, Japanese and Korean pathologists reached a consensus, classifying IPNBs into type l and type 2 IPNBs. IPNBs are more prevalent in male patients in East Asia and are closely related to diseases such as cholelithiasis and schistosomiasis. From a molecular genetic perspective, IPNBs exhibit early genetic variations, and different molecular pathways may be involved in the tumorigenesis of type 1 and type 2 IPNBs. The histological subtypes of IPNBs include gastric, intestinal, pancreaticobiliary, or oncocytic subtypes, but type 1 IPNBs typically exhibit more regular and well-organized histological features than type 2 IPNBs and are more commonly found in the intrahepatic bile ducts with abundant mucin. Due to the rarity of these lesions and the absence of specific clinical and laboratory features, imaging is crucial for the preoperative diagnosis of IPNB, with local bile duct dilation and growth along the bile ducts being the main imaging features. Surgical resection remains the optimal treatment for IPNBs, but negative bile duct margins and the removal of lymph nodes in the hepatic hilum significantly improve the postoperative survival rates for patients with IPNBs.

Keywords

intraductal papillary neoplasm of the bile duct / subclassification / neoplasms / precancerous tissue / prognosis

References

[1] CattellRB, BraaschJW, KahnF. Polypoid epithelial tumors of the bile ducts. N Engl J Med, 1962, 266: 57-61

[2] SchriefersKH. Contribution on tumors of the bile ducts (Report on papillomatosis of the extra and intrahepatic bile ducts). Zentralblatt fur Chirurgie, 1960, 85: 2308-2311

[3] KimHJ, KimMH, LeeSK, et al.. Mucin-hypersecreting bile duct tumor characterized by a striking homology with an intraductal papillary mucinous tumor (IPMT) of the pancreas. Endoscopy, 2000, 32(5): 389-393

[4] ZenY, SasakiM, FujiiT, et al.. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct—an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol, 2006, 44(2): 350-358

[5] ChenTC, NakanumaY, ZenY, et al.. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology, 2001, 34(4): 651-658 Pt 1

[6] SuhKS, RohHR, KohYT, et al.. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology, 2000, 31(1): 12-17

[7] MinagawaN, SatoN, MoriY, et al.. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes. Eur J Surg Oncol, 2013, 39(6): 554-558

[8] BartonJG, BarrettDA, MaricevichMA. Intraductal papillary mucinous neoplasm of the biliary tract: a real disease?. HPB (Oxford), 2009, 11(8): 684-691

[9] ZenY, FujiiT, ItatsuK, et al.. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology, 2006, 44(5): 1333-1343

[10] NakanumaY. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas?. Pathol Int, 2010, 60(6): 419-429

[11] Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. World Health Organization. 2010

[12] NakanumaY, JangKT, FukushimaN, et al.. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci, 2018, 25(3): 181-187

[13] NagtegaalID, OdzeRD, KlimstraD, et al.. The 2019 WHO classification of tumours of the digestive system. Histopathology, 2020, 76(2): 182-188

[14] WuRS, LiaoWJ, MaJS, et al.. Epidemiology and outcome of individuals with intraductal papillary neoplasms of the bile duct. World J Gastrointest Oncol, 2023, 15(5): 843-857

[15] NakanumaY, UesakaK, KakudaY, et al.. Intraductal Papillary Neoplasm of Bile Duct: Updated Clinicopathological Characteristics and Molecular and Genetic Alterations. J Clin Med, 2020, 9(12): 3991

[16] LendvaiG, SzekerczesT, IllyesI, et al.. Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis. Pathol Oncol Res, 2020, 26(1): 3-15

[17] KanjiZS, RochaFG. Premalignant Lesions of the Biliary Tract. Surg Clin North Am, 2019, 99(2): 301-314

[18] ParkHJ, KimSY, KimHJ, et al.. Intraductal Papillary Neoplasm of the Bile Duct: Clinical, Imaging, and Pathologic Features. AJR Am J Roentgenol, 2018, 211(1): 67-75

[19] JangKT, HongSM, LeeKT, et al.. Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection. Virchows Archiv, 2008, 453(6): 589-598

[20] KuboS, NakanumaY, TakemuraS, et al.. Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci, 2014, 21(7): 479-488

[21] KuboS, TanakaS, KinoshitaM, et al.. Development of intraductal papillary neoplasm of the bile duct in patients with occupational cholangiocarcinoma. Virchows Archiv, 2023, 482(4): 745-753

[22] AokiY, MizumaM, HataT, et al.. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes. J Pathol, 2020, 251(1): 38-48

[23] YangCY, HuangWJ, TsaiJH, et al.. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct. Mod Pathol, 2019, 32(11): 1637-1645

[24] XianZH, QinC, CongWM. KRAS mutation and immunohistochemical profile in intraductal papillary neoplasm of the intrahepatic bile ducts. Pathol Res Pract, 2018, 214(1): 105-111

[25] GoeppertB, StichelD, TothR, et al.. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. Gut, 2022, 71(2): 391-401

[26] TomitaH, TanakaK, HirataA, et al.. Inhibition of FGF10-ERK signal activation suppresses intraductal papillary neoplasm of the bile duct and its associated carcinomas. Cell Rep, 2021, 34(8): 108772

[27] TanakaM, ShibaharaJ, IshikawaS, et al.. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. Virchows Archiv, 2019, 474(1): 39-46

[28] SatoY, KinoshitaM, TakemuraS, et al.. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma. Pathol Int, 2017, 67(3): 163-170

[29] NakanumaY, UesakaK, OkamuraY, et al.. Reappraisal of pathological features of intraductal papillary neoplasm of bile duct with respect to the type 1 and 2 subclassifications. Hum Pathol, 2021, 111: 21-35

[30] OnoeS, EbataT, YokoyamaY, et al.. A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (IPNB): a continuous spectrum with papillary cholangiocarcinoma in 181 curatively resected cases. HPB (Oxford), 2021, 23(10): 1525-1532

[31] SasakiM, MatsubaraT, NittaT, et al.. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. PLoS One, 2013, 8(12): e81706

[32] MalekiF, RezazadehF, VarmiraK. MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy. Mol Pharm, 2021, 18(5): 1842-1861

[33] FabrisL, SatoK, AlpiniG, et al.. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology, 2021, 73(S1): 75-85

[34] KimJR, JangKT, JangJY, et al.. Clinicopathologic analysis of intraductal papillary neoplasm of bile duct: Korean multicenter cohort study. HPB (Oxford), 2020, 22(8): 1139-1148

[35] Gordon-WeeksAN, JonesK, HarrissE, et al.. Systematic Review and Meta-analysis of Current Experience in Treating IPNB. Ann Surg, 2016, 263(4): 656-663

[36] KubotaK, JangJY, NakanumaY, et al.. Clinicopathological characteristics of intraductal papillary neoplasm of the bile duct: a Japan-Korea collaborative study. J Hepato-biliary Pancreat Sci, 2020, 27(9): 581-597

[37] WanXS, XuYY, QianJY, et al.. Intraductal papillary neoplasm of the bile duct. World J Gastroenterol, 2013, 19(46): 8595-8604

[38] ZhengQ, RuanSM, ShanQY, et al.. Clinicopathological findings and imaging features of intraductal papillary neoplasm of the bile duct: comparison between contrast-enhanced ultrasound and contrast-enhanced computed tomography. Abdom Radiol (NY), 2019, 44(7): 2409-2417

[39] ZenY, FujiiT, ItatsuK, et al.. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol, 2006, 19(9): 1243-1254

[40] LiuLN, XuHX, ZhengSG, et al.. Ultrasound Findings of Intraductal Papillary Neoplasm in Bile Duct and the Added Value of Contrast-Enhanced Ultrasound. Ultraschall Med, 2015, 36(6): 594-602

[41] ChatterjeeA, Lopes VendramiC, NikolaidisP, et al.. Uncommon Intraluminal Tumors of the Gallbladder and Biliary Tract: Spectrum of Imaging Appearances. Radiographics, 2019, 39(2): 388-412

[42] AslamA, WasnikAP, ShiJ, et al.. Intraductal papillary neoplasm ofthe bile duct (IPNB): CT and MRI appearance with radiology-pathology correlation. Clin Imaging, 2020, 66: 10-17

[43] LiuY, ZhongX, YanL, et al.. Diagnostic performance of CT and MRI in distinguishing intraductal papillary neoplasm of the bile duct from cholangiocarcinoma with intraductal papillary growth. Eur Radiol, 2015, 25(7): 1967-1974

[44] OgawaH, ItohS, NagasakaT, et al.. CT findings of intraductal papillary neoplasm of the bile duct: assessment with multiphase contrast-enhanced examination using multi-detector CT. Clin Radiol, 2012, 67(3): 224-231

[45] IkenoY, SeoS, YamamotoG, et al.. Usefulness of Preoperative (18)F-FDG-PET in Detecting Invasive Intraductal Papillary Neoplasm of the Bile Duct. Anticancer Res, 2018, 38(6): 3677-3682

[46] TakanamiK, HiraideT, KanetaT, et al.. FDG PET/CT findings in malignant intraductal papillary mucinous neoplasm of the bile ducts. Clin Nucl Med, 2010, 35(2): 83-85

[47] YounJM, HwangS, AhnCS, et al.. Clinicopathological Features and Long-Term Outcomes of Intraductal Papillary Neoplasms of the Bile Duct of the Liver: Single-Institution Experience with 146 Patients. J Gastrointest Surg, 2022, 26(7): 1394-1405

[48] LeeS, KimMJ, KimS, et al.. Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI. J Hepatol, 2019, 70(4): 692-699

[49] JooI, LeeJM. Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection. Abdom Imaging, 2013, 38(6): 1334-1350

[50] HongGS, ByunJH, KimJH, et al.. Thread sign in biliary intraductal papillary mucinous neoplasm: a novel specific finding for MRI. Eur Radiol, 2016, 26(9): 3112-3120

[51] WuCH, YehYC, TsueiYC, et al.. Comparative radiological pathological study of biliary intraductal tubulopapillary neoplasm and biliary intraductal papillary mucinous neoplasm. Abdom Radiol (NY), 2017, 42(10): 2460-2469

[52] JinKP, RaoSX, ShengRF, et al.. Skewness of apparent diffusion coefficient (ADC) histogram helps predict the invasive potential of intraductal papillary neoplasms of the bile ducts (IPNBs). Abdom Radiol (NY), 2019, 44(1): 95-103

[53] Jeon SK, Lee JM, Yoo J, et al. Intraductal papillary neoplasm of the bile duct: diagnostic value of MRI features in differentiating pathologic subclassifications-type 1 versus type 2. European radiology, 2023. doi: https://doi.org/10.1007/s00330-023-10491-9. Online ahead of print

[54] YoonJH. Biliary papillomatosis: correlation of radiologic findings with percutaneous transhepatic cholangioscopy. J Gastrointest Liver Dis, 2013, 22(4): 427-433

[55] YehTS, TsengJH, ChiuCT, et al.. Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts. Ann Surg, 2006, 244(2): 248-253

[56] ChungDJ, LeeSK, HaHK, et al.. Multiple biliary papillomatosis: comparison of MR cholangiography with endoscopic retrograde cholangiography. J Comput Assist Tomogr, 2002, 26(6): 968-974

[57] SakamotoE, HayakawaN, KamiyaJ, et al.. Treatment strategy for mucin-producing intrahepatic cholangiocarcinoma: value of percutaneous transhepatic biliary drainage and cholangioscopy. World J Surg, 1999, 23(10): 1038-1043 discussion 1043–1044

[58] ShinIS, MoonJH, LeeYN, et al.. Use of peroral cholangioscopy to screen for neoplastic bile duct lesions in patients with bile duct stones (with videos). Gastrointest Endosc, 2021, 94(4): 776-785

[59] KalaitzakisE, WebsterGJ, OppongKW, et al.. Diagnostic and therapeutic utility of single-operator peroral cholangioscopy for indeterminate biliary lesions and bile duct stones. Eur J Gastroenterol Hepatol, 2012, 24(6): 656-664

[60] ItoiT, SofuniA, ItokawaF, et al.. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc, 2007, 66(4): 730-736

[61] TsuyuguchiT, SakaiY, SugiyamaH, et al.. Endoscopic diagnosis of intraductal papillary mucinous neoplasm of the bile duct. J Hepatobiliary Pancreat Sci, 2010, 17(3): 230-235

[62] LimJH, JangKT. Mucin-producing bile duct tumors: radiological-pathological correlation and diagnostic strategy. J Hepatobiliary Pancreat Sci, 2010, 17(3): 223-229

[63] LuviraV, SomsapK, PugkhemA, et al.. Morphological Classification of Intraductal Papillary Neoplasm of the Bile Duct with Survival Correlation. Asian Pac J Cancer Prev, 2017, 18(1): 207-213

[64] KubotaK, NakanumaY, KondoF, et al.. Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver: a multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci, 2014, 21(3): 176-185

[65] KimKM, LeeJK, ShinJU, et al.. Clinicopathologic features of intraductal papillary neoplasm of the bile duct according to histologic subtype. Am J Gastroenterol, 2012, 107(1): 118-125

[66] YingS, YingM, LiangW, et al.. Morphological classification of intraductal papillary neoplasm of the bile duct. Eur Radiol, 2017, 28(4): 1568-1578

[67] KimJR, LeeKB, KwonW, et al.. Comparison of the Clinicopathologic Characteristics of Intraductal Papillary Neoplasm of the Bile Duct according to Morphological and Anatomical Classifications. J Korean Med Sci, 2018, 33(42): e266

[68] HuclT. Precursors to Cholangiocarcinoma. Gastroenterol Res Pract, 2019, 2019: 1389289

[69] ShyuS, SinghiAD. Cystic biliary tumors ofthe liver: diagnostic criteria and common pitfalls. Hum Pathol, 2021, 112: 70-83

[70] NaritaM, EndoB, MizumotoY, et al.. Multicentric recurrence of intraductal papillary neoplasms of bile duct in the remnant intrahepatic bile duct after curative resection. Int J Surg Case Rep, 2015, 12: 123-127

[71] ChoiJU, HwangS, JungDH, et al.. Living donor liver transplantation for diffuse biliary papillomatosis with malignant change: A case report with 10-year follow-up. Ann Hepatobiliary Pancreat Surg, 2020, 24(2): 209-215

[72] LluísN, Serradilla-MartínM, AchalandabasoM, et al.. Intraductal papillary neoplasms of the bile duct: a European retrospective multicenter observational study (EUR-IPNB study). Int J Surg, 2023, 109(4): 760-771

[73] YouY, ChoiSH, ChoiDW, et al.. Recurrence After Resection for Intraductal Papillary Neoplasm of Bile Duct (IPNB) According to Tumor Location. J Gastrointest Surg, 2020, 24(4): 804-812

[74] TangW, QiuJG, WeiXF, et al.. Endoscopic Endoluminal Radiofrequency Ablation and Single-Operator Peroral Cholangioscopy System (SpyGlass) in the Diagnosis and Treatment of Intraductal Papillary Neoplasm of the Bile Duct: A Case Report and Literature Review. Front Med (Lausanne), 2021, 8: 675720

[75] AraiJ, KatoJ, TodaN, et al.. Long-term survival after palliative argon plasma coagulation for intraductal papillary mucinous neoplasm of the bile duct. Clin J Gastroenterol, 2021, 14(1): 314-318

[76] NatovNS, HortonLC, HegdeSR. Successful endoscopic treatment of an intraductal papillary neoplasm of the bile duct. World J Gastrointest Endosc, 2017, 9(5): 238-242

[77] LeeHS, OhTG, ChungMJ, et al.. Photodynamic Therapy Followed by Left Hepatectomy Used to Treat an Intraductal Papillary Mucinous Neoplasm of the Bile Duct. Korean J Med, 2015, 88(1): 60

[78] CheongCO, LimJH, ParkJS, et al.. Volume-reserving Surgery after Photodynamic Therapy for Biliary Papillomatosis: A Case Report. Korean J Gastroenterol, 2015, 66(1): 55-58

[79] KimJR, JangKT, JangJY. Intraductal papillary neoplasm of the bile duct: review of updated clinicopathological and imaging characteristics. Br J Surg, 2023, 110(9): 1229-1240

[80] UemuraS, HiguchiR, YazawaT, et al.. Prognostic Factors for Surgically Resected Intraductal Papillary Neoplasm of the Bile Duct: A Retrospective Cohort Study. Ann Surg Oncol, 2021, 28(2): 826-834

[81] LuviraV, PugkhemA, BhudhisawasdiV, et al.. Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct. J Gastroenterol Hepatol, 2017, 32(2): 527-533

[82] KimWJ, HwangS, LeeYJ, et al.. Clinicopathological Features and Long-Term Outcomes of Intraductal Papillary Neoplasms of the Intrahepatic Bile Duct. J Gastrointest Surg, 2016, 20(7): 1368-1375

[83] HaradaF, MatsuyamaR, MoriR, et al.. Outcomes of surgery for 2010 WHO classification-based intraductal papillary neoplasm of the bile duct: Case-control study of a single Japanese institution’s experience with special attention to mucin expression patterns. Eur J Surg Oncol, 2019, 45(5): 761-768

[84] SasakiM, MatsubaraT, YonedaN, et al.. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct. Histopathology, 2013, 62(3): 446-457

[85] Albores-SaavedraJ H, KlimstraDS. Tumors of the gallbladder, extrahepatic bile ducts, and vaterian system. AFIP Atlas of Tumor Pathology, 2015, Maryland, American Registry of PathologySilver Spring